HK Stock Market Move | ALPHAMAB-B (09966) rises nearly 7% in the afternoon, JSKN003 has been approved for clinical use before, the company has been removed from the Hang Seng Composite Index.

ALPHAMAB-B (09966) rose nearly 7% in the afternoon, rising 5.45% at the time of publication, to HK$4.64 with a trading volume of HK$37.069 million. On the news front, Conagen Pharmaceuticals earlier announced that their HER2 bispecific antibody drug conjugate JSKN003 has received approval from the National Medical Products Administration Drug Evaluation Center to conduct a Phase III clinical trial, for a comparative study in platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Soochow pointed out that JSKN003 is the company's first ADC product, targeting DS-8201. It is worth noting that Hang Seng Index Company has announced the results of its regular quarterly index adjustments. The Hang Seng Composite Index semi-annual index review coincides with this, which will once again be a major basis for the investment scope of the Hong Kong Stock Connect. Conagen Pharmaceuticals has been removed from the Hang Seng Composite Index early, and Huatai stated that the company may be removed from the Hong Kong Stock Connect list in March, while CICC's report did not mention the company being removed from the Hong Kong Stock Connect.